Skip to main content
Fig. 8 | The Journal of Headache and Pain

Fig. 8

From: Therapeutic novelties in migraine: new drugs, new hope?

Fig. 8

Overview of patients (%) achieving > 50% reduction in migraine days in phase III clinical trials with eptinezumab. A darker bar indicates a higher dose. *PROMISE I; 100 mg vs. placebo, p = 0.0085; 300 mg vs. placebo, p = 0.0001. PROMISE II; 100 mg vs. placebo, p < 0.0001; 300 mg vs. placebo, p < 0.0001

Back to article page
\